A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals

Clinical Infectious Diseases

Volumn 54, Issue 7, 2012, Pages 946-954

  Ehrlich, Hartmut J ^a   Singer, Julia ^a   Berezuk, Gregory ^b   Fritsch, Sandor ^a   Aichinger, Gerald ^a   Hart, Mary Kate ^c   El Amin, Wael ^c   Portsmouth, Daniel ^a   Kistner, Otfried ^a   Barrett, P Noel ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b Baxter BioScience   (United States)

^c DynPort Vaccine Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO;

ADULT; ARTICLE; BIVARIATE ANALYSIS; CELL CULTURE; CONTROLLED STUDY; COUGHING; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; HEADACHE; HUMAN; INFLUENZA VIRUS; MALE; MYALGIA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY; VERO CELL; VIRUS CULTURE; VIRUS INFECTION; VIRUS STRAIN;

ADULT; ANIMALS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CERCOPITHECUS AETHIOPS; DOUBLE-BLIND METHOD; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; PLACEBOS; SEVERITY OF ILLNESS INDEX; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; VERO CELLS; YOUNG ADULT;

EID: 84858125275     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir959     Document Type: Article

References (35)

1. Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377:751-9.
2. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997-1004.
3. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260-7.
4. Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis 2009; 200:1861-9.
5. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513-22. (Pubitemid 44917499)
6. Beran J, Wertzova V, Honegr K, et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009; 9:2.
7. Nichol KL. Heterogeneity of influenza case definitions and implications for interpreting and comparing study results. Vaccine 2006; 24:6726-8. (Pubitemid 46107155)
8. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26. (Pubitemid 15055349)
9. Hothorn T, Hornik K, van de Wiel MA, Zeileis A. A Lego system for conditional inference. Am Stat 2006; 60:257-63. (Pubitemid 44257518)
10. CDC. Update: influenza activity-United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:369-74.
11. CDC. Key facts about influenza (flu) and flu vaccine. Available at: http://www.cdc.gov/flu/keyfacts.htm. Accessed 23 August 2011.
12. Foy HM, Cooney MK, McMahan R, Bor E, Grayston JT. Single-dose monovalent A2-Hong Kong influenza vaccine: Efficacy 14 months after immunization. JAMA 1971; 217:1067-71.
13. Foy HM, Cooney MK, McMahan R. A Hong Kong influenza immunity three years after immunization. JAMA 1973; 226:758-61.
14. Clark A, Potter CW, Jennings R, et al. A comparison of live and inactivated influenza A (H1N1) virus vaccines: 2. Long-term immunity. J Hyg (Lond) 1983; 90:361-70. (Pubitemid 13051662)
15. Ambrose CS, Yi T, Walker RE, Connor EM. Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J 2008; 27:744-8.
16. Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010; 29:806-11.
17. Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis 2010; 10:71.
18. Ohmit SE, Victor JC, Teich ER, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008; 198:312-17.
19. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44.
20. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; (7):CD001269.
21. Kamada M, Nagai T, Kumagai T, et al. Efficacy of inactivated trivalent influenza vaccine in alleviating the febrile illness of culture-confirmed influenza in children in the 2000-2001 influenza season. Vaccine 2006; 24:3618-23.
22. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998; 338:1405-12. (Pubitemid 28221981)
23. Yang CF, Belshe RB, Kemble G, et al. Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine. Vaccine 2010; 28:5128-34.
24. Forrest BD, Steele AD, Hiemstra L, Rappaport R, Ambrose CS, Gruber WC. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine 2011; 29:3633-9.
25. Block SL, Heikkinen T, Toback SL, Zheng W, Ambrose CS. The efficacy of live attenuated influenza vaccine against influenzaassociated acute otitis media in children. Pediatr Infect Dis J 2011; 30:203-7.
26. Clements ML, Betts RF, Murphy BR. Advantage of live attenuated coldadapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet 1984; 1:705-8. (Pubitemid 14171146)
27. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986; 23:66-72. (Pubitemid 16186972)
28. Sears SD, Clements ML, Betts RF, Maassab HF, Murphy BR, Snyder MH. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis 1988; 158:1209-19. (Pubitemid 19023284)
29. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333: 889-93.
30. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21:2207-17.
31. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-96. (Pubitemid 46879994)
32. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1-62.
33. US Department of Health and Human Services. Healthy people 2020: topics and objectives index. Available at: http://www.healthypeople. gov/2020/topicsobjectives2020/pdfs/HP2020objectives.pdf. Accessed 23 August 2011.
34. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009; 8:607-18.
35. Glezen WP. Cell-culture-derived influenza vaccine production. Lancet 2011; 377:698-700.